Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates

Journal of Pharmaceutical Sciences

Volumn 98, Issue 6, 2009, Pages 1962-1979

  Saxena, Vishal ^a   Panicucci, Riccardo ^a   Joshi, Yatindra ^b   Garad, Sudhakar ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Developability assessment; Early drug development; Formulation; Pharmacokinetics; Preformulation; Solid dosage forms

Indexed keywords

AUTOMATION; COMPUTER MODEL; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DECISION MAKING; DOG; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; ELECTRONICS; HUMAN; MONKEY; NONHUMAN; REVIEW; SCIENTIST; SUSPENSION; TOXICITY TESTING;

EID: 67049169036     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21592     Document Type: Article

References (29)

1. Cockburn IM. 2004. The changing structure of the pharmaceutical industry. Health Affairs 23:10-22. (Pubitemid 39107144)
2. Frank RG, Seiguer E. 2003. Generic drug competition in Business Briefings. Pharmagenerics September: 66-70.
3. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:715-771.
4. Accenture Consulting. 2007. The pursuit of high performance through research and development: Understanding pharmaceutical research and development cost drivers. Accenture.
5. Venkatesh S, Lipper RA. 2000. Role of the development scientist in compound lead selection and optimization. J Pharm Sci 89:145-154. (Pubitemid 30120795)
6. Subramaniam S. 2003. Productivity and attrition: Key challenges for biotech and pharma. Drug Discov Today 8:513-515. (Pubitemid 36773663)
7. Watkins KJ. 2002. Fighting the clock. Chem Eng News 80:27-33.
8. Kerns EH, Di L. 2002. Multivariate pharmaceutical profiling for drug discovery. Curr Top Med Chem 2:87-98.
9. Fiese EFG. 2003. General pharmaceutics - The New Physical Pharmacy. J Pharm Sci 92:1131-1342.
10. Balbach S, Korn C. 2004. Pharmaceutical evaluation of early development candidates "the 100 mgapproach". Int J Pharm 275:1-12.
11. Sun D, Yu LX, Hussain MA, Wall DA, Smith RL, Amidon GL. 2004. In vitro testing of drug absorption for drug 'developability' assessment: Forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel 7:75-85.
12. Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW. 2005. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr Top Med Chem 5:1033-1038. (Pubitemid 41582117)
13. Singh SS. 2006. Preclinical Pharmacokinetics: An approach towards safer and efficacious drugs. Curr Drug Metab 7:165-182.
14. Maas J, Kamm W, Hauck G. 2007. An integrated early formulation strategy - From hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66:1-10. (Pubitemid 46412973)
15. Drews J. 2000. Drug discovery: A historical perspective. Science 287:1960-1964. (Pubitemid 30158662)
16. Ratti E, Trist D. 2001. Continuing evolution of the drug discovery process in the pharmaceutical industry. Pure Appl Chem 73:67-75.
17. Garad S. 2004. How to improve the bioavailability of poorly soluble drugs. Am Pharm Rev 7:80-85. (Pubitemid 38628360)
18. Liu X, Fahr A. 2007. Drug delivery strategies for poorly soluble drugs. Expert Opin Drug Deliv 4:403-416. (Pubitemid 47249138)
19. Department of Health and Human Services, Food and Drug Administration. 1997. International conference on harmonisation: Guidelines for the photostability testing of new drug substances and products. Federal Register 62:27115-27122.
20. Meinzer A, Mueller EA, Niese D. 1996. Principles of drug development. In: Lieberman R, Mukherjee A, editors. Transplantation and autoimmunity. Austin, TX: R.G. Landes. pp. 259-267.
21. Choc MG. 1997. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral® vs Sandimmune®. Int J Dermatol 36:1-6. (Pubitemid 28060180)
22. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ, Spagnuolo CJ, Serajuddin ATM. 1994. An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm 105:209-217. (Pubitemid 24103998)
23. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59:603-616. (Pubitemid 47285406)
24. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066. (Pubitemid 29480600)
25. Constantinides PP. 1995. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res 12:1561-1572.
26. Narang AS, Dalmaree D, Gao D. 2007. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 345:9-25. (Pubitemid 350103649)
27. Stella VJ, Nti-Addae KW. 2007. Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev 59:677-694. (Pubitemid 47285410)
28. Alanine A, Nettekoven M, Roberts E, Thomas AW. 2003. Lead generation - Enhancing the success of drug discovery by investing in the hit to lead process. Comb Chem High Throughput Screen 6:51-66. (Pubitemid 36206832)
29. Kuentz M, Nick S, Parrott N, Rothlisberger D. 2006. A strategy for preclinical formulation development using GastroPlus™ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 27:91-99. (Pubitemid 41728259)